CN1313089C - 刺激cpt－1物质在制备减轻体重的组合物中的用途 - Google Patents

刺激cpt－1物质在制备减轻体重的组合物中的用途 Download PDF

Info

Publication number
CN1313089C
CN1313089C CNB038050145A CN03805014A CN1313089C CN 1313089 C CN1313089 C CN 1313089C CN B038050145 A CNB038050145 A CN B038050145A CN 03805014 A CN03805014 A CN 03805014A CN 1313089 C CN1313089 C CN 1313089C
Authority
CN
China
Prior art keywords
cpt
cooc
activating agent
fatty acid
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038050145A
Other languages
English (en)
Chinese (zh)
Other versions
CN1638758A (zh
Inventor
J·N·图帕里
L·E·兰德里
G·龙尼特
F·P·库哈伊达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CN1638758A publication Critical patent/CN1638758A/zh
Application granted granted Critical
Publication of CN1313089C publication Critical patent/CN1313089C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pediatric Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNB038050145A 2002-02-08 2003-02-10 刺激cpt－1物质在制备减轻体重的组合物中的用途 Expired - Fee Related CN1313089C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
US60/354,480 2002-02-08

Publications (2)

Publication Number Publication Date
CN1638758A CN1638758A (zh) 2005-07-13
CN1313089C true CN1313089C (zh) 2007-05-02

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038050145A Expired - Fee Related CN1313089C (zh) 2002-02-08 2003-02-10 刺激cpt－1物质在制备减轻体重的组合物中的用途

Country Status (12)

Country Link
US (4) US20050143467A1 (https=)
EP (1) EP1471906A4 (https=)
JP (2) JP2005523270A (https=)
KR (1) KR20040082417A (https=)
CN (1) CN1313089C (https=)
AU (2) AU2003215111A1 (https=)
BR (1) BR0307421A (https=)
CA (1) CA2474884A1 (https=)
EA (1) EA007029B1 (https=)
IL (1) IL163312A (https=)
MX (1) MXPA04007556A (https=)
WO (1) WO2003066043A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
EA013371B1 (ru) * 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения
WO2005089773A1 (en) * 2004-03-18 2005-09-29 Fasgen, Llc Control of feeding behavior by changing neuronal energy balance
MXPA06013687A (es) * 2004-05-26 2007-10-18 Fasgen Llc Compuestos novedosos, composiciones farmaceuticas que los contienen y metodos para utilizar los mismos.
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
ATE418603T1 (de) * 2005-08-29 2009-01-15 Hoffmann La Roche Kristallstrukturen von carnitine palmitoyltransferase-2 (cpt-2) und deren verwendung
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434160A (en) * 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
US6413545B1 (en) * 1998-09-01 2002-07-02 Access Business Group International Llc Diet composition and method of weight management
KR20090031957A (ko) * 1999-11-12 2009-03-30 더 존스 홉킨스 유니버시티 세포내 말로닐 ＣｏＡ의 수준을 증가시킴에 의한 암의 치료방법
WO2001060174A2 (en) * 2000-02-16 2001-08-23 The Johns Hopkins University School Of Medicine Weight loss induced by reduction in neuropeptide y level
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
US20060241177A1 (en) 2002-07-01 2006-10-26 Kuhadja Francis P Novel compounds, pharmaceutical compositions containing same, and methods of use for same
EA013371B1 (ru) 2002-07-09 2010-04-30 Фасджен, Ллс. Новые соединения, содержащие их фармацевтические композиции и способы их применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434160A (en) * 1980-07-11 1984-02-28 Leopold & Co. Chem. Pharm. Fabrik Gesellschaft M.B.H. Nutrient solution for complete parenteral feeding and for increased energy production
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
US20050143467A1 (en) 2005-06-30
EP1471906A1 (en) 2004-11-03
CA2474884A1 (en) 2003-08-14
US20070087037A1 (en) 2007-04-19
US20050106217A1 (en) 2005-05-19
IL163312A (en) 2011-12-29
CN1638758A (zh) 2005-07-13
US7459481B2 (en) 2008-12-02
US20090124684A1 (en) 2009-05-14
JP2010047594A (ja) 2010-03-04
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
AU2008249144A1 (en) 2008-12-11
EA200401052A1 (ru) 2005-02-24
EP1471906A4 (en) 2006-02-01
EA007029B1 (ru) 2006-06-30
MXPA04007556A (es) 2005-12-05
JP2005523270A (ja) 2005-08-04
BR0307421A (pt) 2004-12-28
AU2003215111A1 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
Konopka et al. Skeletal muscle hypertrophy after aerobic exercise training
da Luz et al. Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats
Neufer et al. Transient regulation of c-fos, αB-crystallin, and hsp70 in muscle during recovery from contractile activity
CN1313089C (zh) 刺激cpt－1物质在制备减轻体重的组合物中的用途
Parrella et al. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells: cross-talk between the cAMP and the retinoic acid signaling pathways
Nakagawara et al. 5′-CMP and 5′-UMP alleviate dexamethasone-induced muscular atrophy in C2C12 myotubes
CN115554309B (zh) 一种药物组合物及其在制备防治精神性疾病和/或亚健康精神状态产品中的应用
RU2004139030A (ru) Применение sgk и nedd в качестве мишеней для диагностических и терапевтических целей
US20160000751A1 (en) Method for treating and/or delaying the degeneration of purkinje cells
Ahmadi Effect of Eight Weeks of Resistance Training with Spirulina Supplementation on Cardiac Troponin T, Brain Natriuretic Peptide, and Creatine Kinase in the Myocardium
RU2540476C1 (ru) Повышение работоспособности
Semanchik et al. Influence of Mechanistic Target of Rapamycin (mTOR)-Regulated Anabolic Pathways on Equine Skeletal Muscle Health
Shoji et al. Lipopolysaccharide stimulates histamine-forming enzyme (histidine decarboxylase) activity in murine dental pulp and gingiva
JP3020111B2 (ja) 体脂肪蓄積低減剤
Diaz-Rosas et al. The sodium borate relieves the hypertrophic damage induced during pregnancy, it improves contractibility, reduces oxidative stress and stimulates cell proliferation
WO2022218320A1 (en) Compositions and methods for promotingglycogen synthase activity and augmenting glycogen storage capability
Lee et al. Cell cycle profile data on splenocytes of high fat diet induced obese mice treated with ferulic acid
RU2734899C1 (ru) Применение водного раствора протран 4-хлор-2-метилфеноксиацетата (хлоркрезацина) для стимулирования статической и динамической работоспособности
RU2734728C1 (ru) Применение протатран 4-хлор-2-метилфеноксиацетата (хлоркрезацина) в 0,9% растворе хлорида натрия для стимулирования статической и динамической работоспособности
Da Silva et al. Involvement of the Soluble Guanylate Cyclase, Nitric Oxide Synthase and Cytokines Pathway in the Anti-Inflammatory Profile of N-Acylhydrazone Derivatives (Jr19)
Federenko et al. Potential benefits of potassium deposition with periodic fluid redistribution using periodic head down tilt during diminished muscular activity
Sarcodie et al. Vitamin C: the known and the unknown
US20100168218A1 (en) Method of reducing food intake
Toziuk et al. Biochemical aspects of KB-28 compound on physically loaded study subjects
Nonaka et al. Therapeutic Effects of Ghrelin and Des-Acyl Ghrelin on Doxorubicin-Induced Cardiotoxicity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070502

Termination date: 20110210